Vilin Bio Med Limited

NSEI:VILINBIO Stock Report

Market Cap: ₹280.4m

Vilin Bio Med Past Earnings Performance

Past criteria checks 0/6

Vilin Bio Med has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 18.2% per year.

Key information

1.7%

Earnings growth rate

-2.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-18.2%
Return on equity-2.1%
Net Margin-3.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vilin Bio Med makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:VILINBIO Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24131-560
30 Jun 24146-270
31 Mar 24161280
31 Dec 23152470
30 Sep 231601580
30 Jun 231421480
31 Mar 231231280
31 Mar 22112090
31 Mar 211171110
31 Mar 201682140

Quality Earnings: VILINBIO is currently unprofitable.

Growing Profit Margin: VILINBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VILINBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare VILINBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VILINBIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).


Return on Equity

High ROE: VILINBIO has a negative Return on Equity (-2.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:48
End of Day Share Price 2024/12/13 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vilin Bio Med Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution